Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: Study with cDNA-expressed systems of the rat

被引:95
作者
Kobayashi, K
Urashima, K
Shimada, N
Chiba, K
机构
[1] Chiba Univ, Lab Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan
[2] Daiichi Pure Chem Co Ltd, Tokyo, Japan
关键词
D O I
10.1124/dmd.31.7.833
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to determine the selectivities of chemical inhibitors for human cytochrome P450 (P450) isoforms toward the corresponding rat P450 isoforms by using cDNA-expressed rat P450s (CYP1A2, CYP2A1, CYP2C6, CYP2C11, CYP2D2, CYP2E1, CYP3A1, and CYP3A2). Among the inhibitor probes for human P450s used in this study, only sulfaphenazole showed a selective inhibitory effect on the activity of the corresponding rat P450 isoform (CYP2C6). Furafylline also preferentially inhibited the activity of rat CYP1A2. However, methoxalen and ketoconazole more strongly inhibited the activities of other P450 isoforms than those of the corresponding rat P450 isoforms, CYP2A1 and CYP3A1/2, respectively. On the other hand, quinidine and aniline had little effect on the activities of the corresponding rat P450 isoforms, CYP2D2, and rat CYP2E1, respectively. These results suggest that chemical probes that have been used for human P450 isoforms do not always exhibit the same selectivity for the corresponding rat P450 isoforms. However, it appears that sulfaphenazole can be used as a selective inhibitor for rat CYP2C6. In addition, furafylline may also be a relatively selective inhibitor for rat CYP1A2.
引用
收藏
页码:833 / 836
页数:4
相关论文
共 14 条
[1]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[2]   SPECIES VARIATION IN THE RESPONSE OF THE CYTOCHROME P-450-DEPENDENT MONOOXYGENASE SYSTEM TO INDUCERS AND INHIBITORS [J].
BOOBIS, AR ;
SESARDIC, D ;
MURRAY, BP ;
EDWARDS, RJ ;
SINGLETON, AM ;
RICH, KJ ;
MURRAY, S ;
DELATORRE, R ;
SEGURA, J ;
PELKONEN, O ;
PASANEN, M ;
KOBAYASHI, S ;
ZHIGUANG, T ;
DAVIES, DS .
XENOBIOTICA, 1990, 20 (11) :1139-1161
[3]  
Bourrie M, 1996, J PHARMACOL EXP THER, V277, P321
[4]   Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes [J].
Eagling, VA ;
Tjia, JF ;
Back, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (02) :107-114
[5]  
Kobayashi K, 2000, CLIN CANCER RES, V6, P3297
[6]   Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat [J].
Kobayashi, K ;
Urashima, K ;
Shimada, N ;
Chiba, K .
BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) :889-896
[7]   THE SPECIFICITY OF INHIBITION OF DEBRISOQUINE 4-HYDROXYLASE ACTIVITY BY QUINIDINE AND QUININE IN THE RAT IS THE INVERSE OF THAT IN MAN [J].
KOBAYASHI, S ;
MURRAY, S ;
WATSON, D ;
SESARDIC, D ;
DAVIES, DS ;
BOOBIS, AR .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (17) :2795-2799
[8]  
Koenigs LL, 1997, DRUG METAB DISPOS, V25, P1407
[9]   Activation of phenacetin O-deethylase activity by α-naphthoflavone in human liver microsomes [J].
Nakajima, M ;
Kobayashi, K ;
Oshima, K ;
Shimada, N ;
Tokudome, S ;
Chiba, K ;
Yokoi, T .
XENOBIOTICA, 1999, 29 (09) :885-898
[10]   P450 IN THE RAT AND MAN - METHODS OF INVESTIGATION, SUBSTRATE SPECIFICITIES AND RELEVANCE TO CANCER [J].
NEDELCHEVA, V ;
GUT, I .
XENOBIOTICA, 1994, 24 (12) :1151-1175